Mortality and Causes of Death 2015 &amp; 2030: A Comparison

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

Sydney Jennings

FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Luke Halpern

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

Related Content

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

Sydney Jennings

FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Luke Halpern

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.